Check out your Company Bowl for anonymous work chats.
Grifols today announced it has acquired 10% of Bloodbuy, a cloud-based marketplace that facilitates buying and selling of blood components in the U.S. Bloodbuy?s proprietary technology platform and computer-based algorithms enable regional blood-collection centers to expand their customer base across the U.S., while providing hospitals and other healthcare providers greater access to vital blood components, efficiently and efficaciously connecting supply and demand. The investment forms part of Grifols? ongoing commitment to leading technologies and solutions that reinforce and complement its core businesses. Bloodbuy will offer synergies to Grifols? Bio Supplies Division and its Diagnostic Division?s leading transfusion medicine business.
Grifols to acquire Green Cross’ Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers, for a total amount of US$460 million. Grifols will become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year. The transaction is part of Grifols’ sustainable global growth strategy to ensure patients worldwide have safe and secure access to life-saving plasma-derived medicines. Furthermore, the operation aligns with Grifols’ commitment to helping countries reach self-sufficiency of life-sustaining plasma-derived medicines.
Grifols today announced the beginning of the production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. Grifols continues to lead initiatives to combat COVID-19 with the development of the first specific drug. Grifols is leading the production of this potential anti-COVID-19 passive immune therapy as part of a collaboration with U.S. health authorities. For more information please see the press release.
Grifols today has received FDA approval for its Procleix Panther System featuring Automation Ready Technology (ART) for use with the following U.S.-licensed products: Procleix Ultrio Elite Assay, Procleix West Nile Virus Assay, Procleix Zika Virus Assay and the Procleix Babesia Assay. ART technology features significant hardware and software improvements that support blood-banking operations of all sizes, such as instrument networkability and information sharing. The Procleix Panther System featuring ART has been available since October 2019 in all markets accepting the CE mark.
Grifols delivered strong results in 2019, reporting revenues of 5.1 billion euros, a 13.6% increase over the previous year. The EBITDA increased 17.3% to 1.4 billion euros and profits grew to 625 million euros. Grifols’ long-term sustainable growth strategy continued to deliver solid results across all divisions and regions.
Grifols today announced that the European Commission has approved U.S.-based Rigel Pharmaceuticals' TAVLESSE® (fostamatinib) for the treatment of chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments. In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. The launch of TAVLESSE® in Europe and Turkey, where Grifols has exclusive rights, reinforces Grifols’ commercial strategy and reflects the company’s commitment to continue expanding its product portfolio to benefit patients. For more information:
Grifols today reinforced its leadership in treating diseases with immunoglobulins (IG) as it launched Xembify®, the company’s first 20% subcutaneous immunoglobulin therapy for the treatment of patients with primary immunodeficiency (PI). With Xembify, the company continues to expand its industry-leading portfolio of plasma-derived medicines to enhance the health and well-being of patients around the world.
Grifols today at the CTAD conference in San Diego released new and complete data from its breakthrough clinical trial on Alzheimer’s disease, AMBAR, strengthening previous results that show a reduction in the progression of the disease in patients with mild-to-moderate Alzheimer’s. New neuroimaging data show less neuronal damage in patients receiving the plasma proteins albumin and immunoglobulin, the mainstays of the AMBAR protocol. Grifols also announced another clinical trial in 2020, AMBAR II, to complement the just-completed study.
Grifols expands in Latin America with the start of production of its new blood-collection systems plant in Campo Largo, Brazil. With an annual capacity in excess of 10 million blood collection bags, the more than 5,500-square-meter plant is expected to gradually increase output to serve the broader Latin American region. http://glassdoor.com/slink.htm?key=vMHJO
Grifols publishes its 2018 CSR report, an in-depth review of the company’s social, environmental and economic achievements. The report highlights Grifols’ firm commitment and pledge of transparency to stakeholders such as donors, patients, medical professionals, employees and society as a whole.
